Imipramine Hydrochloride

CHEMBL1692 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
316.9 g/mol
LogP
Phase
4

This hydrochloride salt of imipramine is the most commonly used formulation of this tricyclic antidepressant for treating depression, panic disorder, and nocturnal enuresis. It inhibits the reuptake of norepinephrine and serotonin, elevating mood over several weeks of treatment. Anticholinergic side effects including dry mouth, constipation, and urinary retention are common.

Khối lượng phân tử

316,9000 g/mol

TPSA

6,50 Ų

Lĩnh vực điều trị

Cơ chế tác dụng

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl

InChI

InChI=1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H

Molecular Formula

C19H25ClN2

HBD / HBA

1 / 2

Liên kết có thể quay

4

Nguyên tử nặng

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This hydrochloride salt of imipramine is the most commonly used formulation of this tricyclic antidepressant for treating depression, panic disorder, and nocturnal enuresis. It inhibits the reuptake of norepinephrine and serotonin, elevating mood over several weeks of treatment. Anticholinergic side effects including dry mouth, constipation, and urinary retention are common.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Imipramine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1692. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 8228. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.